Companies Cryptocurrencies
Kodiak Sciences Inc
Kodiak Sciences Inc
Exchange: NasdaqGM
IPO Date: 04/10/2018
CEO: DR. Victor Perlroth
Biotechnology Healthcare 🔗
  • KOD
  • 102
  • 5250408960
    market cap
  • -3.199997
If you bought

shares of Kodiak Sciences Inc (KOD) on
You would have made
Old Price $12 Current Price $12

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. The company is headquartered in Palo Alto, California and currently employs 34 full-time employees. The firm is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The firm in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The firm has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.

Address: 2631 Hanover St Palo Alto CALIFORNIA 94304

Stay updated.